Jazz Pharmaceuticals Q3 revenue up 7% to $1.13 billion; adjusted profit outlook raised
Jazz Pharmaceuticals reported third-quarter 2025 total revenue of $1.13 billion, up 7% from a year earlier, and GAAP net income of $251.4 million, or $4.08 per diluted share, compared with $215.1 million, or $3.42 per share, in the prior-year quarter. The company raised its 2025 non-GAAP adjusted net income guidance to $475 million to $525 million from $300 million to $350 million, but nine-month GAAP results show a net loss of $559.6 million due to a large acquired in-process R&D charge and litigation settlements.
Key points
- Q3 2025 total revenues were $1,126.1 million, up from $1,055.0 million in Q3 2024.
- GAAP net income was $251.4 million ($4.08 per diluted share) versus $215.1 million ($3.42) a year earlier.
- 2025 non-GAAP adjusted net income guidance rose to $475 million-$525 million from $300 million-$350 million.
- Nine-month GAAP net loss was $559.6 million, compared with net income of $369.0 million in the prior-year period.
The filing
Written by AI on Nov 8, 2026, 1:11 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.